期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 25, 期 11, 页码 2211-2216出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2019.06.017
关键词
Haploidentical; Post-transplant cyclophosphamide; Myeloablative; Total body; Irradiation; GRFS; CGRFS
Although myeloablative conditioning (MAC) before haploidentical donor transplant (HIDT) with post-transplant cyclophosphamide is being increasingly used, the optimal preparative regimen remains unclear. In our initial trial, the feasibility of HIDT following a MAC preparative regimen using fludarabine and 12 Gy of total-body irradiation was demonstrated in 30 patients. We now present long-term outcome results, including an additional 52 patients, now with 47 months (16 to 96) median follow-up. Median patient age was 42 (19 to 61) years. The most common diagnoses were acute myelogenous leukemia (51%) and acute lymphoblastic leukemia (33%), and 39% had a high/very high disease risk index (DRI). Engraftment was universal with no cases of primary or secondary graft failure. Grade 3 to 4 acute graft-versus-host disease (GVHD) and moderate to severe chronic GVHD occurred in 17% and 23%, respectively. Nonrelapse mortality (NRM) was 7% at 1 year and 13% at 4 years. Estimated 4-year overall survival (OS), disease-free survival, and cumulative incidence of relapse (CIR) were 67%, 60%, and 27%, respectively. CIR was significantly higher in patients with high/very high-versus low/intermediate-risk DRI (38% versus 20%, P=.032), which led to inferior 4-year OS (50% versus 77%, P=.001). Median time to systemic immunosuppressive therapy (IST) discontinuation was 7.8 months, with 84% of patients off 1ST at 2 years post-transplant. Current GHVD-free, relapse-free survival (CGRFS) at 2, 3, and 4 years was 60%, 57%, and 60%, respectively. This approach to MAC HIDT results in universal engraftment; low rates of NRM, infection, and clinically significant GVHD; and relatively rapid 1ST discontinuation, resulting in high rates of CGRFS and survival. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据